Ponatinib Therapy for Chronic-Phase CML: Impact of Depth of Response on Survival and Prior Nilotinib Exposure on Ponatinib-Associated Vascular Events
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Cancer Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
Blood Cancer J 2023 Aug 11;13(1)122, MG Abdelmagid, A Al-Kali, MR Litzow, KH Begna, WJ Hogan, MS Patnaik, SK Hashmi, MA Elliott, H Alkhateeb, OS Karrar, F Fleti, MH Elnayir, CE Rivera, HS Murthy, JM Foran, MA Kharfan-Dabaja, T Badar, DS Viswanatha, KK Reichard, N Gangat, A TefferiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.